Fosamax (Alendronate Sodium) Products Liability Litigation (No. II)
The causation theory in Fosamax (Alendronate Sodium) litigation centers on the drug's mechanism of suppressing bone turnover through osteoclast inhibition, which can lead to microdamage accumulation, resulting in atypical femoral fractures and osteonecrosis of the jaw. FDA warnings from 2026 highlight the risks of atypical fractures, especially with long-term use, and emphasize monitoring patients on prolonged therapy. Scientific studies support that extended bisphosphonate use (over 5 years) correlates with increased fracture risk, with specific features such as transverse fracture orientation and cortical thickening indicating atypical femur fractures.
550
Pending actions
1,293
Total actions filed
Active
Status
05/23/2011
Established
Filing deadline
No specific current filing deadlines or statutes of limitations are publicly detailed in recent court orders or legal notices. Active case management orders from 2025 suggest ongoing procedural updates, but exact cut-off dates are not publicly available.
Who qualifies
Plaintiffs must have used Fosamax for a duration that raises concern about adverse effects, typically exceeding 5 years, and must have a confirmed diagnosis of injuries such as osteonecrosis of the jaw or atypical femoral fractures. Use must be consistent with prescribed therapeutic doses, and injuries must be supported by medical records demonstrating a causal link to Fosamax use.
Products involved
- Fosamax (Alendronate Sodium)
Alleged injuries
- osteonecrosis of the jaw (ONJ)
- atypical femoral fractures (AFF)
Bellwether trials
As of early 2026, the MDL-2243 Fosamax litigation has active bellwether trials scheduled for 2026, with some verdicts already reported. Recent updates indicate ongoing case resolutions, with settlement offers ranging from approximately $285,000 to $1.5 million per case. The litigation remains active, with most cases either settled or adjudicated, and no new verdicts or specific trial dates publicly announced beyond 2026.
Lead counsel
- James R. Dugan II (Dugan Law Firm)
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
